Background/Aims: Regulatory T cells (Tregs) can suppress immunologic damage in myocardial ischaemia/reperfusion injury (MIRI), however, the isolation and ex vivo expansion of these cells for clinical application remains challenging. Here, we investigated whether the IL-2/anti-IL-2 complex (IL-2C), a mediator of Treg expansion, can attenuate MIRI in mice. Methods: Myocardial I/R was surgically induced in male C57BL/6 mice, aged 8-10 weeks, that were randomly assigned to 1) sham group (Sham), 2) Phosphate Buffered Saline (PBS), 3) IL-2-anti-IL-2 Ab complex (IL-2C), or 4) sham group, 5) PBS, 6) IL-2C after MIRI, or 7) IL-2C, 8) IL-2C+anti-CD25 mAbs, or 9) IL-2C; 10) IL-2C+anti-TGF-b1 mAbs, 11) IL-2C+anti-IL-10 mAbs. The following parameters were measured at different time points: infarct area, myocardial apoptosis, splenocytes, the inhibitory function of Tregs, and presence of inflammatory factors. In addition, immunohistochemistry analysis was performed. Results: We observed that Tregs were activated in response to MIRI. IL-2C administered before MIRI induced Treg expansion in both spleen and heart, attenuated Th1 and Th17 cell numbers, improved myocardial function, and attenuated both infiltration of inflammatory cells and apoptosis after MIRI. Furthermore, IL-2C administration reduced expression of inflammatory cytokines in the heart and attenuated proliferation of splenic cells. Depletion of Tregs with anti-CD25 mAb abrogated the beneficial effects of IL-2C. However, IL-2C-mediated myocardial protection was not dependent on either IL-10 or TGF-b. In addition, IL-2C administration after MIRI did not reduce infarct area, but did improve myocardial function slightly and reduced myocardial fibrosis. Conclusion: Our results demonstrate that IL-2C-induced Treg expansion attenuates MIRI and improves myocardial recovery in vivo, suggesting that IL-2C is a promising therapeutic target for myocardial IRI.
Introduction
Early restoration of blood flow through an occluded coronary artery is the most effective therapy to reduce infarct size and improve clinical outcome after acute myocardial infarction [1] . However, reperfusion after ischaemia itself causes additional complications, including cardiomyocyte death and an increase in infarct size due to a process called myocardial ischaemia/reperfusion (I/R) injury. The pathogenesis of MIRI is multifactorial, with inflammation being a common feature. There are considerable data indicating important roles for various elements of the immune response in MIRI [2] .
CD4+ T-cells, a heterogeneous cell population that can be further subdivided into T-helper (Th) Th1, Th2 and Th17 and regulatory T-cells (Tregs) by their function, mediate adaptive immune responses that can be harmful during MIRI. Previous reports have demonstrated that interferon (IFN)-γ secreted by Th1 cells and interleukin (IL)-17A secreted by γδT-cells and Th17 cells promote progression of MIRI [3, 4] . Tregs are a subset of T-cells with an immune-modulatory function, commonly identified by expression of CD4 and CD25 on their cell surface and expression of the transcription factor Forkhead box P3 (Foxp3) in the nucleus [5] . They are capable not only of modulating the adaptive immune response by preventing effector T-cell proliferation/function but also of inhibiting the innate immune response [6, 7] . Tregs convey suppressive action through cell-to-cell contact-mediated inhibition of immune cells and/or secretion of inhibitory factors such as IL-10 and transforming growth factor (TGF)-β1 [8] . Previous publications have reported that adoptive transfer of Tregs is beneficial in kidney, brain, liver and myocardial ischaemia/reperfusion (I/R) injury (MIRI) [9] [10] [11] [12] [13] . However, adoptive transfer of Tregs requires larger numbers of donors or in vitro stimulation and has proven difficult to translate into the clinical setting.
Mice were subjected to 30 minutes of LAD ischaemia followed by varying periods of reperfusion. Shamoperated animals were subjected to the same surgical procedures, except that the suture was passed under the LAD but not tied. Echocardiographic and haemodynamic analyses were performed prior to sacrifice. The infarct area was determined using Evans blue and 2, 3,5-triphenyltetrazolium chloride (TTC) staining. The Evens blue-negative stained portion (ischaemic/reperfused tissue or area at risk [AAR] ) was isolated and used for all assays including real-time PCR, Western blotting, and biochemical and immunohistological measurements [21] .
Treatment and groups C57BL/6 mice were subject to sham treatment or 30 minutes ischaemia followed by 1 hour reperfusion, and all parameters were examined at 4 hours, 1 day, 3 days, 7 days, or 14 days.
To elucidate the role of IL-2C in MIRI, C57BL/6 mice were randomly assigned to 3 groups. 1) sham group (Sham), 2) myocardial I/R group that received PBS (PBS), 3) myocardial I/R group that received IL-2C (IL-2C). IL-2C was mixed with anti-IL-2 (JES6-1) (R&D Systems) at a 1:5 ratio (1 mg of recombinant murine IL-2 and 5 mg of anti-IL-2), and incubated at 37°C for 30 minutes. IL-2C or PBS were intraperitoneally administered to mice for 3 consecutive days, beginning 5 days before MIRI. Both the sham operation group and the PBS group were used for controls. Blood, cardiac tissues, and spleen were harvested at different time points after MIRI.
Next, IL-2C was administered for 3 consecutive days, beginning 1 day after MIRI in order to investigate the effect of IL-2C on reperfusion. Infarct area, cardiac function and histological analyses were performed on days 1, 5 and 14.
To investigate the mechanism of IL-2C's effect on MIRI, C57BL/6 mice were randomly assigned to one of two groups: 1) IL-2C group (IL-2C) or 2) IL-2C group receiving PC61, an anti-CD25 antibody (IL-2C/ PC61). To investigate the mechanism of Treg function in MIRI, C57BL/6 mice were randomly assigned to one of three groups: 1) IL-2C group (IL-2C); 2) IL-2C group receiving anti-TGF-b1 antibodies (IL-2C+anti-TGF-b1); or 3) IL-2C group received anti-IL-10 antibodies (IL-2C+anti-IL-10).
To deplete Tregs, anti-CD25 the PC61 antibody (Bio-XCell, West Lebanon, NH) was administered to mice at a dose of 0.3 mg/mouse for 2 consecutive days, beginning 1 day before MIRI. Depletion of Foxp3+CD4+ cells was confirmed by flow cytometry analysis of the spleen. In the TGF-b-blocking experiments, 150 mg of anti-TGF-b antibody (AB-100-NA; R&D Systems, Minneapolis, MN) or anti-IL-10 antibody or rabbit IgG isotype control antibody (eBioscience, San Diego, CA) was intraperitoneally administered to mice on day 24 and day 0 before MIRI.
Echocardiographic and heamodynamic analysis of cardiac function
A Vevo 2100 high-resolution microimaging system with a 30 MHz transducer was used (Visualsonic, Toronto, Ontario, Canada). Mice were anaesthetized with 1.5% isoflurane and two-dimensional echocardiographic views of the mid-ventricular short axis and parasternal long axes were obtained. Left ventricular (LV) fractional shortening (FS) and LV ejection fraction (EF) were calculated from digital images using a standard formula as previously described [22, 23] . Echocardiographic acquisition and analysis were performed by a technician who was blinded to treatment groups.
For haemodynamic performance measurements, a 1.4 French micromanometer-tipped catheter (SPR-671, Millar Instruments, Houston, TX) was inserted into the right carotid artery and then advanced into the LV. LV end-diastolic pressure (LVEDP) was measured, and maximal (LV +dp/dtmax.) and minimal (LV -dp/ dtmin.) first derivative of LV pressure rise and fall were calculated.
Infarct area assessment
Infarct size after I/R injury was determined as previously described [24] . Briefly, at the end of a 4-hour reperfusion period, mice were anaesthetized, the LAD was re-occluded at the previous ligation, and 1 ml of 2.0% Evans blue (Sigma-Aldrich, St. Louis, MO) was injected. The heart was quickly excised, immediately frozen, and sliced. Sections were then incubated in a 1% 2, 3,5-triphenyltetrazolium chloride (TTC, Sigma-Aldrich, St. Louis, MO) solution and digitally photographed. Left ventricular area, area at risk (AAR) and infarct area were determined by computerized planimetry using Image-Pro Plus software (Media Cybernetics Inc., Bethesda, Maryland).
Cellular Physiology and Biochemistry

Serum troponin T Blood concentrations of troponin T were measured as an index of cardiac cellular damage using the quantitative rapid assay kit (Roche Diagnostics GmbH, Mannheim, Germany) as previously described [25, 26] .
Myocardial apoptosis
For terminal deoxynucleotidyl-transferase mediated dUTP nick-end labelling (TUNEL) staining, hearts were fixed in 4% paraformaldehyde, embedded in paraffin, cut into 4-5-µm thickness sections and treated according to manufacturer's instructions using the In Situ Cell Death Detection kit (Roche Diagnostics GmbH, Mannheim, Germany). Following this, sections were co-stained with anti-sarcomeric actin antibody (Sigma-Aldrich, St. Louis, MO) to specifically mark cardiomyocytes. TRITC goat anti-mouse antibody was used as secondary antibody. Total nuclei were stained with DAPI. More than 5 fields in >3 different sections/ animal were examined.
Cardiac caspase-3 activity was measured as previously described [27] using a caspase colorimetric assay kit following the manufacturer's instructions (Chemicon, Temecula, CA). Absorbance of p-nitroaniline cleaved by caspase was measured at 405 nm using a microplate reader (ELx800, Bio-Tek Instruments, USA). The results were standardized to the sham group for comparison of fold change in caspase-3 activity.
Flow Cytometry
The heart-draining lymph nodes were harvested from sham mice and myocardial I/R mice at different time points. After administration of PBS, IL-2C or PC/61, splenic monocytes were isolated from mice. FicollPaque Plus and RCLB were used to remove the erythrocytes. The CD45 
Foxp3
+ Tregs were stained with anti-CD4-FITC and anti-CD25-PE Abs, followed by staining with anti-Foxp3-APC Ab after fixation and permeabilization according to the manufacturer's instructions.
To characterize splenic DCs, cells were stained with CD11c, CD86，and MHC-II Ab for 30 min. Flow cytometry was performed using a FACSCalibur (BD Immunocytometry Systems, USA) and all analyses, including MFI (mean fluorescence intensity), were performed using FlowJo software (Treestar Inc., OR, USA). 
Cell Proliferation
To assess effects on cell proliferation, splenocytes were isolated using Ficoll-Paque (GE Healthcare) and cultured at 2 x 10 5 cells/well in flat-bottomed 96-well plates and stimulated with purified soluble anti-CD3 antibody (1 g/ml, R & D Systems) at 37°C in 5% CO2 for 72 h. The cells were pulsed with 1 Ci of [3H] thymidine for the last 16 hours and harvested with an automatic cell harvester (Pharmacia). Thymidine incorporation was assessed using a liquid scintillation counter (LKB Wallac, Perkin Elmer). 
Tregs and T-Effector Cell
Real-time PCR
Total RNA was extracted from cultured cells or tissues using Trizol (Invitrogen, Carlsbad, CA) and reverse transcribed into cDNA using the PrimeScript RT reagent kit (Takara Biotechnology, Dalian, China) according to the manufacturer's instructions. mRNA levels of target genes were quantified using SYBR Green Master Mix (Takara Biotechnology, Dalian, China) with ABI PRISM 7900 Sequence Detector system (Applied Biosystems, Foster City, CA). Each reaction was performed in duplicate, and changes in relative gene expression were normalized to GAPDH levels using the relative threshold cycle method (Table 1) .
Immunohistochemistry and Masson staining
For the detection of inflammatory cells, one cryosection from each of blocks A, B and D of 3-, 7-and 14-day samples were stained with anti-myeloperoxidase (MPO, Abbiotec, UK), anti-Mac-2 (AbDSerotec, UK), anti-CD45 (eBioscience, USA), anti-CD31, anti-PNCA, and anti-Foxp3 (eBioscience, USA) overnight at 4°C, followed by respective secondary HRP-conjugated antibodies for 1 h at room temperature. Positive cells were visualized with DAB, and nuclei were counterstained with haematoxylin. Five fields (200 magnification) in both the PIZ and NIZ on each cryosection from three blocks per heart were analysed and averaged. Furthermore, fibrous areas were stained with Masson trichrome.
Statistical Analysis
The results are expressed as the mean ± SD unless otherwise indicated. Comparisons between two groups were performed using Student's t test. One-way ANOVA was used for multiple comparisons between ≥3 groups, followed by the Holm-Sidak test. GraphPad Prism 6.0 was used for the statistical analysis. The significance level was set at p<0.05.
Results
Treg Cells Become Activated in Response to MIRI
To test for Treg activation after MIRI, we analysed the heart-draining lymph nodes. Here, increased frequencies of Treg cells were found in mLNs on days 3, 7, and 14 post-MI compared with sham-operated animals analysed on day 7 after surgery ( Fig. 1A) . Absolute numbers of Treg cells were also increased, peaking on day 7. In addition to heart-draining lymph nodes, we evaluated Treg cell infiltration into the healing infarct. Compared with sham-operated mice, the numbers of Treg cells were increased in the infarct border on days 3 and 7 post-MI and post-MIRI (Fig. 1B) . [16] . IL-2C induced significant expansion of Foxp3+CD4+ Tregs in both spleen and heart on day 5 ( Fig. 2A and B ). In comparison with normal animals, the size of the spleen was significantly increased ( Fig. 2A) . Immunohistochemistry staining demonstrated that in cardiac tissues Tregs were elevated 5-fold (Fig. 2B) , indicating that the IL-2/Anti-IL-2 mAb complex expands Tregs in a MIRI model.
Expansion of CD4
IL-2/Anti-IL-2 mAb Complex Treatment Ameliorates MIRI
The extent of injury and heart dysfunction were assayed 4 hours and 1 day after initiation of reperfusion. With similar AAR, the infarct size/AAR was significantly smaller in IL-2C-treated mice than in wild-type mice (Fig. 3A) . In parallel, we observed improved cardiac function, indicated by elevated EF and FS, in IL-2C mice after myocardial I/R compared with wild-type mice. Less serious injury was also apparent from lower levels of serum cTnT being observed in IL-2C mice (Fig. 3B) . These results suggest that IL-2C is protective against myocardial I/R injury.
IL-2/Anti-IL-2 mAb Complex Treatment affected the percentage of different monocytes
We next analysed splenocytes using FACS and investigated whether IL-2C protection was dependent changes in immune cells other than Tregs in the spleen. First, we found that the percentage and number of CD4 + T-cells was increased significantly 2 days after the end of [28, 29] and identified a role for NKT cells in oral tolerance [30] . Surprisingly, IL-2C injection promoted NKT cells. However, this treatment did not affect the phenotype of dendritic cells with respect to CD86 and MHC-II expression (Fig. 4) .
IL-2C Attenuates Cardiomyocyte Apoptosis after I/R in vivo
Apoptosis contributes significantly to myocardial I/R injury [31] . We hypothesized that the role of IL-2C in myocardial I/R is associated with its effects on cardiomyocyte apoptosis. To test this hypothesis, we carried out terminal deoxynucleotidyl-transferase mediated dUTP nick-end labelling (TUNEL) staining of LV sections from different experimental groups 4 h after myocardial I/R. As shown in Fig. 5A and B, IL-2C treatment significantly decreased the number of TUNEL-positive cardiomyocytes compared to control, suggesting that IL-2C treatment inhibits the extent of cardiomyocyte apoptosis induced by Tregs. Concomitantly, caspase 3 activity in ischaemic myocardium was also down-regulated by IL-2C treatment (Fig. 5C) .
To understand the mechanisms through which IL-2C inhibits cardiomyocyte apoptosis, we examined expression of the Bcl-2 family by real-time polymerase chain reaction. Administration of IL-2C in vivo resulted in a decreased Bax/Bcl-2 ratio after myocardial I/R (Fig. 5D) .
IL-2C Reduces Cardiac Immune Cells and Fibrosis
Previous studies using IL-2C to elevate Tregs demonstrated suppressed infiltration of inflammatory cells in atherosclerotic lesions and cardiac tissue [17, 19] . Here, we found that total CD45
+ leukocytes were significantly decreased in heart by IL-2C treatment. proliferation was unaffected by IL-2C. Furthermore, cardiac fibrosis was also significantly decreased in response to MIRI on day 28 following IL-2C treatment, and microvessel density was increased in the IL-2C-treated group compared with the PBS-treated group (Fig. 6) . 
IL-2/Anti-IL-2 mAb Complexes Attenuate Splenocyte Proliferation and Cardiac Proinflammatory Mediators
To determine whether induction of Tregs by IL-2/anti-IL-2 mAb complex affected the proliferative ability of splenocytes, we examined their proliferation in response to anti-CD3 antibodies. After culturing splenocytes for 3 days with anti-CD3 antibodies, proliferation in the IL-2/anti-IL-2 mAb complex-treated mice was attenuated up to 36% compared with control mice (Fig. 7A) . In addition, Treg expansion using the IL-2/anti-IL-2 mAb complex effectively attenuated CD4 + T cell proliferation in vitro compared with control mice (Fig. 7B) . We further investigated changes in local inflammatory cytokines after Treg expansion and found that pro-inflammatory cytokines TNF-α, IFN-g, IL-12, and IL-17A mRNA were down-regulated on day 7 after IR. However, anti-inflammatory cytokines TGF-b1 and IL-10 and M2-induced IL-13, Arginase 1, and CD206 were all up-regulated by IL-2C compared to control mice (Fig. 8) .
Treg Depletion, but Not TGF-β1 and IL-10 Neutralization, Results in Impaired Remodelling
Here, we investigated whether depletion of Tregs altered the effects of IL-2C. When anti-CD25 antibody (PC61) was administered shortly after injection of IL-2C, expansion of Tregs in the spleen was completely abrogated (Fig. 9A ). In addition, infarct size/AAR was significantly larger in IL-2C/PC61 than the IL-2C group (Fig. 9B) . In parallel, we observed depressed cardiac function, as indicated by elevated EF, in IL-2C/PC61 mice after myocardial I/R compared with IL-2C alone (Fig. 9C) .
To assess the role of IL-10 or TGF-b1 in IL-2C-mediated cardiac protection from MIRI, we administered anti-IL-10R mAb or anti-TGF-b1 mAb after IL-2C treatment. We found that neutralizing anti-IL-10R or anti-TGF-b treatment did not abrogate the beneficial effects of IL-2C (Fig. 10) . 
IL-2/Anti-IL-2 mAb Complex Treatment after MIRI Improves Myocardial Fibrosis and Cardiac Function, but Not Infarct Area
To investigate the effects of IL-2C after the onset of reperfusion, IL-2C was administered for 3 consecutive days beginning 1 day after MIRI. We found that IL-2C administration after MIRI also induced significant expansion of Foxp3+CD4+ Tregs in both spleen and heart on day 5 (data not shown). However, the infarct size/AAR was not comparable between groups on day 1 (Fig. 11A) . Surprisingly, cardiac function in the IL-2C group was slightly improved on day 5, although this trend did not reach statistical significance (Fig. 11B) . In parallel, we observed reduction of pro-inflammatory mediators after IL-2C treatment (Fig. 11C ) and significant reduction of myocardial fibrosis on day 14 (Fig. 11D) .
Discussion
Previous studies in our laboratory demonstrated that the adoptive transfer of in vitroactivated Tregs suppressed MIRI, whereas freshly isolated Tregs had no effect [32] . However, adoptive transfer therapy using Tregs is limited by inadequate purity of isolated Treg cell populations, insufficient numbers for transfer, and potential instability [33] . In this study, we demonstrate an alternative to adoptive transfer using selective in vivo expansion of Treg numbers. Low doses of IL-2 complexed with an anti-IL-2 neutralizing antibody (JES6-1) (IL-2C) induced a sustained increase in both systemic and cardiac Tregs. Our data also demonstrate that IL-2C therapy can be used to attenuate MIRI by selectively expanding in Ischaemia-reperfusion triggers a vigorous inflammatory response, augmented by the generation and release of various cytokines, chemokines, and adhesion molecules, which ultimately exacerbate tissue injury [34] . Recently, the pathogenic function of Th1 cells in MIRI was convincingly demonstrated using murine systems [35] . Additional evidence suggests that Th17 cells and interleukin (IL)-17, which are related to autoimmune diseases, may play an important role in MIRI [4] . In contrast, other studies have demonstrated that CD4+CD25+Foxp3+ Tregs exert a protective effect against pathology [32] .
We first observed that activated Treg cells appear in response to MIRI, consistent with previous reports that Treg cells are detected in heart tissue with MIRI [32] . In addition, we observed a rapid infiltration of Tregs in heart draining lymph nodes, beginning at 3 days and peaking at 7 days post-reperfusion, suggesting specific recruitment of Tregs from the peripheral blood to the infarct, and from the heart to immune organs, which is driven by MIRI.
IL-2 plays a critical role in regulating homeostasis of Tregs [36] . We found that IL-2C induced sustained increases in Treg numbers in heart and spleen after MIRI. Although the # P>0.05, *P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001.
The mechanisms underlying the suppressive effects of Tregs in vivo appear to be complex. Apoptosis has been proposed as an important mechanism for cell death in reperfused ischaemic myocardium [31] . This mechanism could be regulated by oxygen free radicals, cytokines such as TNF-α and IL-6, and neutrophil accumulation [37] . A previous study in our laboratory illustrated that Tregs can directly protect neonatal rat cardiomyocytes from LPS-induced apoptosis, and this protection is dependent on cell-cell contact and IL-10 expression, resulting in ameliorated cardiac remodelling [13] . From our collective results, which demonstrate that IL-2C significantly attenuated cardiomyocyte apoptosis after IR injury, we infer that inhibition of apoptosis was the major mechanism for Treg-exerted protection from IR injury. The Bcl-2 family consists of pro-and anti-apoptotic members, and the balance between pro-and anti-apoptotic proteins determines whether cells survive or undergo apoptosis after a stimulus or injury. Our in vivo results show that IL-2C downregulates caspase-3 activity and the ratio of pro-apoptotic (Bax) to anti-apoptotic (Bcl-2) proteins. To further explore this finding, we used PC/61 to deplete CD25+ Tregs. Our data demonstrated that Treg depletion resulted in increased infarct size, myocardial injury, and cardiac dysfunction.
IL-10 and TGF-β1 are key mediators of Tregs during pathology [8] , illustrated well within the tumour and inflammation microenvironment [38] [39] [40] . Moreover, previous reports have demonstrated that both of these factors showed protective effects in MIRI [41, 42] . We observed increased levels of IL-10 and TGF-β1 in infarcted hearts after IL-2C treatment. We infer that infiltrated Treg cells are the source of increased IL-10 and TGF-β1. Surprisingly, anti-IL-10R or anti-TGF-β1 Abs did not cancel the protective effect on MIRI, although observed effects were somewhat milder than that seen in control Tregs. Taken together, these data suggest that IL-2C-mediated cardiac protection against Tregs might not be dependent on a single mechanism of suppression. Both CD4+ Th1-and Th17-derived cytokines, including IFN-g and IL-17, contribute to the development of MIRI [4, 35] . In this study, IL-2C therapy effectively prevented IFN-g, IL-12, TNF-α and IL-17 secretion in infarcted heart, indicating that Treg expansion induced by IL-2C suppresses the ability of Th1 and Th17 cells to secrete cytokines, which is another important mechanism for Treg function.
Neutrophil recruitment plays a major role in myocardial damage after I/R [43] . We showed that Tregs restrict the infiltration of neutrophils. Previously, depletion of IL-17A was shown to inhibit neutrophil infiltration in the heart after IR [4] , so we infer that downregulation of IL-17A here partially contributes to the observed decrease in neutrophils.
Treg cells have also been reported to affect the differentiation of macrophages. Liu et al.'s [44] research showed that Treg cells promote the differentiation of M2 anti-inflammatory macrophages and inhibited M1 pro-inflammatory macrophages. M2-like macrophages activated by Tregs have well known anti-inflammatory characteristics and are an integral component of the wound-healing processes [45] . Consistently, experimental modulation of macrophage polarization towards an M2 state has been previously demonstrated to improve wound healing post-IR [46] . Alternative macrophage activation is initiated in response to IL-10 or TGF-β. We show here that IL-10, TGF-β1, IL-13, Arginase 1 and CD206 were significantly increased in heart tissue after IL-2C treatment, indicating M2-like macrophage differentiation. Production of IL-10 and TGF-β1 by M2-like cells themselves might have further contributed to the M2-containing milieu in situ. However, we cannot exclude Treg cell-mediated contactdependent mechanisms that may also contribute to monocyte/macrophage polarization. In addition, cardiac fibrosis was also significantly increased on day 28 after IL-2C treatment in the IR model, suggesting that IL-2C contributes to improved cardiac healing. Previous reports demonstrate that IL-13, which was strongly induced by CD28-SA treatment, synergizes with TGF-β1 to promote collagen synthesis in myofibroblasts [45] . These results indicate that the differentiation of M2 by Tregs could be partially responsible for improved healing observed after MIRI in the IL-2C-treated group.
The majority of previous experimental studies on post-MI healing have demonstrated that Tregs play a protective role in this process [13, 19, 32, 45] . However, Mathes et al. found Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry that endogenous and MHC-II non-restricted Foxp3+ T-cells could drive MIRI [47] . From this, we infer the following: 1) these endogenous and MHC-II non-restricted Foxp3+ T-cells were inflammatory, and their inhibitory ability and expression of inflammation mediators, such as IFN-g, IL-10, and TGF-β1, were unknown; and 2) the overactive inflammation observed three days after MIRI help convert conventional Foxp3+ T-cells to IFN-g+Foxp3+ T-cells. In contrast, Tregs expanded by IL-2C produce a large amounts of IL-10 and TGF-β1 in our study, exerting powerful inhibitory effects on MIRI.
Conclusion
Treatment with IL-2C attenuates MIRI and improves cardiac recovery after MIRI by expanding Tregs, decreasing myocardial apoptosis and infiltration of inflammatory cells, and increasing M2 and associated anti-inflammatory factors, all of which are dependent on CD25+ Tregs but neither IL-10 nor TGF-b1. Considering its convenience of manipulation and safety, IL-2C is a promising candidate for clinical application in MIRI. 
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